Header Logo

Connection

MALCOLM BRENNER to Hematopoietic Stem Cell Transplantation

Back to Details
This is a "connection" page, showing publications MALCOLM BRENNER has written about Hematopoietic Stem Cell Transplantation.
MALCOLM BRENNER
Connection Strength
4.124
Hematopoietic Stem Cell Transplantation
  1. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood. 2015 Jun 25; 125(26):4103-13.
    View in: PubMed
    Score: 0.257
  2. Antiviral T-cell therapy. Immunol Rev. 2014 Mar; 258(1):12-29.
    View in: PubMed
    Score: 0.237
  3. Cellular therapy for cancer: let there be light. Tissue Antigens. 2012 Jan; 79(1):1-3.
    View in: PubMed
    Score: 0.204
  4. T-cell therapy after hematopoietic stem cell transplantation. Curr Opin Hematol. 2007 Nov; 14(6):616-24.
    View in: PubMed
    Score: 0.153
  5. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood. 2006 Sep 15; 108(6):1797-808.
    View in: PubMed
    Score: 0.138
  6. CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors. Bone Marrow Transplant. 2005 Jun; 35(12):1127-32.
    View in: PubMed
    Score: 0.129
  7. Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients. Haematologica. 2023 Jul 01; 108(7):1840-1850.
    View in: PubMed
    Score: 0.113
  8. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood. 2003 Sep 15; 102(6):2292-9.
    View in: PubMed
    Score: 0.112
  9. Cord blood transplantation for nonmalignant disorders: early functional immunity and high survival. Blood Adv. 2023 05 09; 7(9):1823-1830.
    View in: PubMed
    Score: 0.112
  10. Is retroviral gene marking too dangerous to use? Cytotherapy. 2003; 5(3):190-3.
    View in: PubMed
    Score: 0.109
  11. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021 05 13; 137(19):2585-2597.
    View in: PubMed
    Score: 0.097
  12. Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients. Blood Adv. 2019 09 24; 3(18):2689-2695.
    View in: PubMed
    Score: 0.087
  13. Use of gene marking technologies in oncology. Forum (Genova). 1998 Oct-Dec; 8(4):342-53.
    View in: PubMed
    Score: 0.081
  14. EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood. 2018 11 29; 132(22):2351-2361.
    View in: PubMed
    Score: 0.081
  15. High Incidence of Autoimmune Disease after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease. Biol Blood Marrow Transplant. 2018 08; 24(8):1643-1650.
    View in: PubMed
    Score: 0.079
  16. Current Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphocytic Leukemia: Success, Failure and Future Perspectives-A Single-Center Experience, 2008 to 2016. Biol Blood Marrow Transplant. 2018 07; 24(7):1424-1431.
    View in: PubMed
    Score: 0.078
  17. BMT beats autoimmune disease. Nat Med. 1998 Feb; 4(2):153-5.
    View in: PubMed
    Score: 0.078
  18. Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome. Biol Blood Marrow Transplant. 2018 03; 24(3):537-541.
    View in: PubMed
    Score: 0.077
  19. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 Nov 01; 35(31):3547-3557.
    View in: PubMed
    Score: 0.075
  20. Gene marking and gene therapy for transplantation medicine. J Hematother. 1996 Oct; 5(5):553-5.
    View in: PubMed
    Score: 0.071
  21. Placental blood transplant: who will benefit? Nat Med. 1996 Sep; 2(9):969-70.
    View in: PubMed
    Score: 0.070
  22. Transfer of marker genes into hemopoietic progenitor cells. Cytokines Mol Ther. 1996 Sep; 2(3):193-200.
    View in: PubMed
    Score: 0.070
  23. Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation. Mol Ther. 2016 Apr; 24(4):823-31.
    View in: PubMed
    Score: 0.067
  24. Gene-marking and haemopoietic stem-cell transplantation. Blood Rev. 1995 Dec; 9(4):220-5.
    View in: PubMed
    Score: 0.067
  25. The contribution of marker gene studies to hemopoietic stem cell therapies. Stem Cells. 1995 Sep; 13(5):453-61.
    View in: PubMed
    Score: 0.066
  26. Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies. Biol Blood Marrow Transplant. 2015 Jul; 21(7):1266-72.
    View in: PubMed
    Score: 0.064
  27. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014 Jun 25; 6(242):242ra83.
    View in: PubMed
    Score: 0.060
  28. Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood. 2014 Jun 19; 123(25):3895-905.
    View in: PubMed
    Score: 0.060
  29. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin Cancer Res. 2014 Apr 15; 20(8):2215-25.
    View in: PubMed
    Score: 0.059
  30. Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma. Bone Marrow Transplant. 2014 Feb; 49(2):219-22.
    View in: PubMed
    Score: 0.058
  31. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013 Oct 24; 122(17):2965-73.
    View in: PubMed
    Score: 0.057
  32. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013 Nov; 21(11):2113-21.
    View in: PubMed
    Score: 0.056
  33. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013 Jun 27; 121(26):5113-23.
    View in: PubMed
    Score: 0.056
  34. Gene transfer into human hematopoietic progenitor cells: a review of current clinical protocols. J Hematother. 1993; 2(1):7-17.
    View in: PubMed
    Score: 0.055
  35. Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation. Blood. 2013 Jan 03; 121(1):207-18.
    View in: PubMed
    Score: 0.054
  36. Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease. J Allergy Clin Immunol. 2012 Jan; 129(1):176-83.
    View in: PubMed
    Score: 0.050
  37. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood. 2010 Nov 25; 116(22):4700-2.
    View in: PubMed
    Score: 0.046
  38. Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin's lymphoma in adolescents and young adults at a single institution. Leuk Lymphoma. 2010 Apr; 51(4):664-70.
    View in: PubMed
    Score: 0.045
  39. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010 Feb 04; 115(5):925-35.
    View in: PubMed
    Score: 0.044
  40. Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. Lancet. 2009 Sep 12; 374(9693):912-20.
    View in: PubMed
    Score: 0.043
  41. Overview of gene therapy clinical progress including cancer treatment with gene-modified T cells. Hematology Am Soc Hematol Educ Program. 2009; 675-81.
    View in: PubMed
    Score: 0.041
  42. Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1245-52.
    View in: PubMed
    Score: 0.041
  43. Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1298-304.
    View in: PubMed
    Score: 0.041
  44. Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Neurology. 2008 Oct 21; 71(17):1326-34.
    View in: PubMed
    Score: 0.041
  45. Transmission of integrated human herpesvirus-6 in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Sep; 40(6):563-6.
    View in: PubMed
    Score: 0.037
  46. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant. 2007 Aug; 13(8):913-24.
    View in: PubMed
    Score: 0.037
  47. Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Jun; 39(11):705-9.
    View in: PubMed
    Score: 0.037
  48. The continuing contribution of gene marking to cell and gene therapy. Mol Ther. 2007 Apr; 15(4):666-76.
    View in: PubMed
    Score: 0.036
  49. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood. 2004 May 15; 103(10):3979-81.
    View in: PubMed
    Score: 0.029
  50. American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol Ther. 2003 Aug; 8(2):180-7.
    View in: PubMed
    Score: 0.028
  51. Cells of the hepatic side population contribute to liver regeneration and can be replenished with bone marrow stem cells. Haematologica. 2003 Apr; 88(4):368-78.
    View in: PubMed
    Score: 0.028
  52. Immune therapy for EBV infections after hemopoietic stem-cell transplant. Cytotherapy. 2002; 4(5):433-4.
    View in: PubMed
    Score: 0.025
  53. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000 Feb 15; 95(4):1502-5.
    View in: PubMed
    Score: 0.022
  54. Gene-marked autologous hematopoietic stem cell transplantation of autoimmune disease. J Clin Immunol. 2000 Jan; 20(1):1-9.
    View in: PubMed
    Score: 0.022
  55. Cure of leukemia. Semin Hematol. 1999 Oct; 36(4 Suppl 7):73-83.
    View in: PubMed
    Score: 0.022
  56. In?Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. Mol Ther. 2018 12 05; 26(12):2727-2737.
    View in: PubMed
    Score: 0.020
  57. Gene marking. Gene Ther. 1996 Apr; 3(4):278-9.
    View in: PubMed
    Score: 0.017
  58. Clonal Dynamics In Vivo of Virus Integration Sites of T Cells Expressing a Safety Switch. Mol Ther. 2016 04; 24(4):736-45.
    View in: PubMed
    Score: 0.017
  59. Gene transfer and bone marrow transplantation. Cold Spring Harb Symp Quant Biol. 1994; 59:691-7.
    View in: PubMed
    Score: 0.015
  60. Aggressive peripheral CD70-positive T-cell lymphoma associated with severe chronic active EBV infection. Pediatr Blood Cancer. 2012 Oct; 59(4):758-61.
    View in: PubMed
    Score: 0.013
  61. Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother. 2008 Sep; 31(7):665-74.
    View in: PubMed
    Score: 0.010
  62. Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications. Blood. 2004 Feb 01; 103(3):1011-9.
    View in: PubMed
    Score: 0.007
  63. Hematopoietic and immunomodulatory effects of lytic CD45 monoclonal antibodies in patients with hematologic malignancy. Biol Blood Marrow Transplant. 2003 Apr; 9(4):273-81.
    View in: PubMed
    Score: 0.007
  64. Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines. Curr Top Microbiol Immunol. 2001; 258:221-9.
    View in: PubMed
    Score: 0.006
  65. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996 May; 2(5):551-5.
    View in: PubMed
    Score: 0.004
  66. Vectors in cancer therapy: how will they deliver? Cancer Gene Ther. 1995 Dec; 2(4):291-7.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.